| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
16,920,000 |
| Market
Cap: |
2.77(M) |
| Last
Volume: |
25,688,722 |
Avg
Vol: |
24,206,070 |
| 52
Week Range: |
$0.164 - $0.164 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Windtree Therapeutics is a clinical-stage, biopharmaceutical company focused on the development of therapeutics to address unmet medical needs in acute care markets. Co.'s primary product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure. In addition, Co. cardiovascular drug product candidates include rostafuroxin, for the treatment of hypertension in patients with a specific genetic profile. Co.'s pulmonary product candidate portfolio consists of a KL4 surfactant platform to address a range of serious respiratory conditions in children and adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,500 |
24,812 |
| Total Buy Value |
$0 |
$0 |
$2,250 |
$15,204 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simonson Steven |
SVP, Chief Medical Officer |
• • – |
2018-12-28 |
4 |
D |
$5.00 |
$37,010 |
D/D |
(7,402) |
39,835 |
|
- |
|
| Tattory John Andrew |
SVP & CFO |
• • – |
2018-12-28 |
4 |
D |
$5.00 |
$40,035 |
D/D |
(8,007) |
36,203 |
|
- |
|
| Peacock Bruce |
Director |
• • – |
2018-12-24 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
16,160 |
|
- |
|
| Mahady Joseph M |
Director |
• • – |
2018-12-24 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
16,160 |
|
- |
|
| Leone John R |
Director |
• • – |
2018-12-24 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
16,212 |
|
- |
|
| Center Laboratories, Inc. |
10% Owner |
– – • |
2018-12-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,551,750 |
|
- |
|
| Lees Pharmaceutical Holdings Ltd |
10% Owner |
– – • |
2018-12-21 |
4/A |
B |
$3.31 |
$39,459,228 |
I/I |
9,874,799 |
12,794,970 |
1.5 |
- |
|
| Lph Ii Investments Ltd |
10% Owner |
– – • |
2018-12-21 |
4/A |
B |
$3.31 |
$5,994,205 |
D/D |
1,810,938 |
2,352,605 |
2.45 |
- |
|
| Simonson Steven |
SVP, Chief Development Officer |
• • – |
2018-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
150 |
47,237 |
|
- |
|
| Leone John R |
Director |
• • – |
2018-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
650 |
1,212 |
|
- |
|
| Fraser Craig |
President and CEO |
• • – |
2018-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
350 |
99,535 |
|
- |
|
| Peacock Bruce |
Director |
• • – |
2018-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
850 |
1,160 |
|
- |
|
| Mahady Joseph M |
Director |
• • – |
2018-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
850 |
1,160 |
|
- |
|
| Lees Pharmaceutical Holdings Ltd |
10% Owner |
– – • |
2018-11-08 |
4/A |
A |
$0.00 |
$0 |
D/D |
66,900 |
2,920,171 |
|
- |
|
| Lees Pharmaceutical Holdings Ltd |
10% Owner |
– – • |
2018-04-04 |
4 |
B |
$4.80 |
$2,600,002 |
I/I |
541,667 |
2,853,271 |
1.5 |
- |
|
| Tattory John Andrew |
SVP & CFO |
• • – |
2017-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
883,144 |
884,215 |
|
- |
|
| Simonson Steven |
SVP, Chief Development Officer |
• • – |
2017-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
940,564 |
941,756 |
|
- |
|
| Fraser Craig |
President and CEO |
• • – |
2017-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,976,190 |
1,983,690 |
|
- |
|
| Fraser Craig |
President and CEO |
• • – |
2016-10-28 |
4 |
B |
$2.05 |
$15,381 |
D/D |
7,500 |
7,500 |
2.81 |
- |
|
| Mahady Joseph M |
Director |
• • – |
2016-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,348 |
6,211 |
|
- |
|
| Leone John R |
Director |
• • – |
2016-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,348 |
11,250 |
|
- |
|
| Peacock Bruce |
Director |
• • – |
2016-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,348 |
6,211 |
|
- |
|
| Rosenthale Marvin E |
Director |
• • – |
2016-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,348 |
6,211 |
|
- |
|
| Templeton Mary B Esq |
SVP, Gen Counsel & Corp Sec |
• • – |
2016-06-30 |
4 |
A |
$1.93 |
$2,250 |
I/I |
1,166 |
9,270 |
|
- |
|
| Tattory John Andrew |
SVP & CFO |
• • – |
2016-06-30 |
4 |
A |
$1.93 |
$2,100 |
I/I |
1,088 |
6,555 |
|
- |
|
619 Records found
|
|
Page 5 of 25 |
|
|
